Skip to main content
Top
Published in: Clinical and Translational Allergy 1/2012

Open Access 01-12-2012 | Review

Mechanisms of allergen-specific immunotherapy

Authors: Hiroyuki Fujita, Michael B Soyka, Mübeccel Akdis, Cezmi A Akdis

Published in: Clinical and Translational Allergy | Issue 1/2012

Login to get access

Abstract

Allergen-specific immunotherapy (allergen-SIT) is a potentially curative treatment approach in allergic diseases. It has been used for almost 100 years as a desensitizing therapy. The induction of peripheral T cell tolerance and promotion of the formation of regulatory T-cells are key mechanisms in allergen-SIT. Both FOXP3+CD4+CD25+ regulatory T (Treg) cells and inducible IL-10- and TGF-β-producing type 1 Treg (Tr1) cells may prevent the development of allergic diseases and play a role in successful allergen-SIT and healthy immune response via several mechanisms. The mechanisms of suppression of different pro-inflammatory cells, such as eosinophils, mast cells and basophils and the development of allergen tolerance also directly or indirectly involves Treg cells. Furthermore, the formation of non-inflammatory antibodies particularly IgG4 is induced by IL-10. Knowledge of these molecular basis is crucial in the understanding the regulation of immune responses and their possible therapeutic targets in allergic diseases.
Appendix
Available only for authorised users
Literature
1.
go back to reference Larche M, Akdis CA, Valenta R: Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006, 6 (10): 761-71.PubMedCrossRef Larche M, Akdis CA, Valenta R: Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006, 6 (10): 761-71.PubMedCrossRef
2.
go back to reference Akdis M, Akdis CA: Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov. 2009, 8 (8): 645-60.PubMedCrossRef Akdis M, Akdis CA: Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov. 2009, 8 (8): 645-60.PubMedCrossRef
3.
go back to reference Akdis CA: Allergy and hypersensitivity: mechanisms of allergic disease. Curr Opin Immunol. 2006, 18 (6): 718-26.PubMedCrossRef Akdis CA: Allergy and hypersensitivity: mechanisms of allergic disease. Curr Opin Immunol. 2006, 18 (6): 718-26.PubMedCrossRef
4.
go back to reference Akdis M, Akdis CA: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2007, 119 (4): 780-91.PubMedCrossRef Akdis M, Akdis CA: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2007, 119 (4): 780-91.PubMedCrossRef
5.
go back to reference Akdis M: Interleukins, from 1 to 37, and interferon-gamma: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011, 127 (3): 701-721. e70PubMedCrossRef Akdis M: Interleukins, from 1 to 37, and interferon-gamma: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011, 127 (3): 701-721. e70PubMedCrossRef
6.
go back to reference Soyer OU, Akdis M, Akdis CA: Mechanisms of subcutaneous allergen immunotherapy. Immunol Allergy Clin North Am. 2011, 31 (2): 175-90.PubMedCrossRef Soyer OU, Akdis M, Akdis CA: Mechanisms of subcutaneous allergen immunotherapy. Immunol Allergy Clin North Am. 2011, 31 (2): 175-90.PubMedCrossRef
7.
go back to reference Wang M: Peanut-induced intestinal allergy is mediated through a mast cell-IgE-FcepsilonRI-IL-13 pathway. J Allergy Clin Immunol. 2010, 126 (2): 306-16. 316 e1-12PubMedCentralPubMedCrossRef Wang M: Peanut-induced intestinal allergy is mediated through a mast cell-IgE-FcepsilonRI-IL-13 pathway. J Allergy Clin Immunol. 2010, 126 (2): 306-16. 316 e1-12PubMedCentralPubMedCrossRef
8.
go back to reference Knol EF: Requirements for effective IgE cross-linking on mast cells and basophils. Mol Nutr Food Res. 2006, 50 (7): 620-4.PubMedCrossRef Knol EF: Requirements for effective IgE cross-linking on mast cells and basophils. Mol Nutr Food Res. 2006, 50 (7): 620-4.PubMedCrossRef
12.
go back to reference Akdis M: Healthy immune response to allergens: T regulatory cells and more. Curr Opin Immunol. 2006, 18 (6): 738-44.PubMedCrossRef Akdis M: Healthy immune response to allergens: T regulatory cells and more. Curr Opin Immunol. 2006, 18 (6): 738-44.PubMedCrossRef
13.
go back to reference Iwakura Y: Functional specialization of interleukin-17 family members. Immunity. 2011, 34 (2): 149-62.PubMedCrossRef Iwakura Y: Functional specialization of interleukin-17 family members. Immunity. 2011, 34 (2): 149-62.PubMedCrossRef
14.
go back to reference Wang YH: IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med. 2007, 204 (8): 1837-47.PubMedCentralPubMedCrossRef Wang YH: IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med. 2007, 204 (8): 1837-47.PubMedCentralPubMedCrossRef
15.
go back to reference Goswami S: Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma. Nat Immunol. 2009, 10 (5): 496-503.PubMedCrossRef Goswami S: Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma. Nat Immunol. 2009, 10 (5): 496-503.PubMedCrossRef
16.
go back to reference Bilsborough J: IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2006, 117 (2): 418-25.PubMedCrossRef Bilsborough J: IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2006, 117 (2): 418-25.PubMedCrossRef
17.
go back to reference Dillon SR: Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004, 5 (7): 752-60.PubMedCrossRef Dillon SR: Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004, 5 (7): 752-60.PubMedCrossRef
19.
go back to reference Liew FY, Pitman NI, McInnes IB: Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010, 10 (2): 103-10.PubMedCrossRef Liew FY, Pitman NI, McInnes IB: Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010, 10 (2): 103-10.PubMedCrossRef
20.
go back to reference Akkoc T: Increased activation-induced cell death of high IFN-gamma-producing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseases. J Allergy Clin Immunol. 2008, 121 (3): 652-658. e1PubMedCrossRef Akkoc T: Increased activation-induced cell death of high IFN-gamma-producing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseases. J Allergy Clin Immunol. 2008, 121 (3): 652-658. e1PubMedCrossRef
21.
go back to reference Meyer N: IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol. 2010, 125 (4): 858-865. e10PubMedCrossRef Meyer N: IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol. 2010, 125 (4): 858-865. e10PubMedCrossRef
22.
go back to reference Solarewicz-Madejek K: T cells and eosinophils in bronchial smooth muscle cell death in asthma. Clin Exp Allergy. 2009, 39 (6): 845-55.PubMedCrossRef Solarewicz-Madejek K: T cells and eosinophils in bronchial smooth muscle cell death in asthma. Clin Exp Allergy. 2009, 39 (6): 845-55.PubMedCrossRef
23.
go back to reference Trautmann A: T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest. 2000, 106 (1): 25-35.PubMedCentralPubMedCrossRef Trautmann A: T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest. 2000, 106 (1): 25-35.PubMedCentralPubMedCrossRef
24.
go back to reference Trautmann A: T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. J Allergy Clin Immunol. 2002, 109 (2): 329-37.PubMedCrossRef Trautmann A: T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. J Allergy Clin Immunol. 2002, 109 (2): 329-37.PubMedCrossRef
25.
go back to reference Zimmermann M: TNF-like weak inducer of apoptosis (TWEAK) and TNF-alpha cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immunol. 2011, 127 (1): 200-7. 207 e1-10PubMedCrossRef Zimmermann M: TNF-like weak inducer of apoptosis (TWEAK) and TNF-alpha cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immunol. 2011, 127 (1): 200-7. 207 e1-10PubMedCrossRef
26.
go back to reference Anderson AE: Seasonal changes in suppressive capacity of CD4+ CD25+ T cells from patients with hayfever are allergen-specific and may result in part from expansion of effector T cells among the CD25+ population. Clin Exp Allergy. 2009, 39 (11): 1693-9.PubMedCrossRef Anderson AE: Seasonal changes in suppressive capacity of CD4+ CD25+ T cells from patients with hayfever are allergen-specific and may result in part from expansion of effector T cells among the CD25+ population. Clin Exp Allergy. 2009, 39 (11): 1693-9.PubMedCrossRef
27.
go back to reference Han D: Allergen-specific IL-10-secreting type I T regulatory cells, but not CD4(+)CD25(+)Foxp3(+) T cells, are decreased in peripheral blood of patients with persistent allergic rhinitis. Clin Immunol. 2010, 136 (2): 292-301.PubMedCrossRef Han D: Allergen-specific IL-10-secreting type I T regulatory cells, but not CD4(+)CD25(+)Foxp3(+) T cells, are decreased in peripheral blood of patients with persistent allergic rhinitis. Clin Immunol. 2010, 136 (2): 292-301.PubMedCrossRef
28.
go back to reference Karagiannidis C: Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004, 114 (6): 1425-33.PubMedCrossRef Karagiannidis C: Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004, 114 (6): 1425-33.PubMedCrossRef
29.
go back to reference Akdis CA, Akdis M: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011, 127 (1): 18-27. quiz 28-9PubMedCrossRef Akdis CA, Akdis M: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011, 127 (1): 18-27. quiz 28-9PubMedCrossRef
30.
go back to reference Gri G: CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008, 29 (5): 771-81.PubMedCentralPubMedCrossRef Gri G: CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008, 29 (5): 771-81.PubMedCentralPubMedCrossRef
31.
go back to reference Kearley J: Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med. 2005, 202 (11): 1539-47.PubMedCentralPubMedCrossRef Kearley J: Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med. 2005, 202 (11): 1539-47.PubMedCentralPubMedCrossRef
32.
go back to reference Kearley J, Robinson DS, Lloyd CM: CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J Allergy Clin Immunol. 2008, 122 (3): 617-24 e6.PubMedCentralPubMedCrossRef Kearley J, Robinson DS, Lloyd CM: CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J Allergy Clin Immunol. 2008, 122 (3): 617-24 e6.PubMedCentralPubMedCrossRef
33.
go back to reference Meiler F: Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy. 2008, 63 (11): 1455-63.PubMedCrossRef Meiler F: Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy. 2008, 63 (11): 1455-63.PubMedCrossRef
34.
go back to reference Akdis M, Blaser K, Akdis CA: T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol. 2005, 116 (5): 961-8. quiz 969PubMedCrossRef Akdis M, Blaser K, Akdis CA: T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol. 2005, 116 (5): 961-8. quiz 969PubMedCrossRef
35.
go back to reference Palomares O: Role of Treg in immune regulation of allergic diseases. Eur J Immunol. 2010, 40 (5): 1232-40.PubMedCrossRef Palomares O: Role of Treg in immune regulation of allergic diseases. Eur J Immunol. 2010, 40 (5): 1232-40.PubMedCrossRef
36.
go back to reference Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003, 4 (4): 330-6.PubMedCrossRef Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003, 4 (4): 330-6.PubMedCrossRef
37.
go back to reference Chatila TA: JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest. 2000, 106 (12): R75-81.PubMedCentralPubMedCrossRef Chatila TA: JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest. 2000, 106 (12): R75-81.PubMedCentralPubMedCrossRef
38.
go back to reference Chatila TA: Role of regulatory T cells in human diseases. J Allergy Clin Immunol. 2005, 116 (5): 949-59. quiz 960PubMedCrossRef Chatila TA: Role of regulatory T cells in human diseases. J Allergy Clin Immunol. 2005, 116 (5): 949-59. quiz 960PubMedCrossRef
39.
go back to reference Ono M: Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature. 2007, 446 (7136): 685-9.PubMedCrossRef Ono M: Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature. 2007, 446 (7136): 685-9.PubMedCrossRef
40.
41.
go back to reference Klunker S: Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. J Exp Med. 2009, 206 (12): 2701-15.PubMedCentralPubMedCrossRef Klunker S: Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. J Exp Med. 2009, 206 (12): 2701-15.PubMedCentralPubMedCrossRef
43.
go back to reference Akdis M: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004, 199 (11): 1567-75.PubMedCentralPubMedCrossRef Akdis M: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004, 199 (11): 1567-75.PubMedCentralPubMedCrossRef
44.
go back to reference Jutel M: IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003, 33 (5): 1205-14.PubMedCrossRef Jutel M: IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003, 33 (5): 1205-14.PubMedCrossRef
46.
go back to reference Carballido JM: T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J Immunol. 1993, 150 (8 Pt 1): 3582-91.PubMed Carballido JM: T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J Immunol. 1993, 150 (8 Pt 1): 3582-91.PubMed
47.
go back to reference Platts-Mills T: Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet. 2001, 357 (9258): 752-6.PubMedCrossRef Platts-Mills T: Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet. 2001, 357 (9258): 752-6.PubMedCrossRef
48.
go back to reference Akdis CA, Akdis M: Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol. 2009, 123 (4): 735-46. quiz 747-8PubMedCrossRef Akdis CA, Akdis M: Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol. 2009, 123 (4): 735-46. quiz 747-8PubMedCrossRef
49.
go back to reference Schandene L: B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol. 1994, 152 (9): 4368-74.PubMed Schandene L: B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol. 1994, 152 (9): 4368-74.PubMed
50.
go back to reference Rak S, Hakanson L, Venge P: Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J Allergy Clin Immunol. 1990, 86 (5): 706-13.PubMedCrossRef Rak S, Hakanson L, Venge P: Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J Allergy Clin Immunol. 1990, 86 (5): 706-13.PubMedCrossRef
51.
go back to reference Lebman DA, Edmiston JS: The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect. 1999, 1 (15): 1297-304.PubMedCrossRef Lebman DA, Edmiston JS: The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect. 1999, 1 (15): 1297-304.PubMedCrossRef
52.
go back to reference Borsutzky S: TGF-beta receptor signaling is critical for mucosal IgA responses. J Immunol. 2004, 173 (5): 3305-9.PubMedCrossRef Borsutzky S: TGF-beta receptor signaling is critical for mucosal IgA responses. J Immunol. 2004, 173 (5): 3305-9.PubMedCrossRef
53.
go back to reference Chen W: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003, 198 (12): 1875-86.PubMedCentralPubMedCrossRef Chen W: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003, 198 (12): 1875-86.PubMedCentralPubMedCrossRef
54.
go back to reference Onishi Y: Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA. 2008, 105 (29): 10113-8.PubMedCentralPubMedCrossRef Onishi Y: Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA. 2008, 105 (29): 10113-8.PubMedCentralPubMedCrossRef
55.
go back to reference Ke Y, Kapp JA: Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells. J Immunol. 1996, 156 (3): 916-21.PubMed Ke Y, Kapp JA: Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells. J Immunol. 1996, 156 (3): 916-21.PubMed
56.
go back to reference Zhou J: CD8+ gammadelta T regulatory cells mediate kidney allograft prolongation after oral exposure to alloantigen. Transpl Int. 2008, 21 (7): 679-87.PubMedCrossRef Zhou J: CD8+ gammadelta T regulatory cells mediate kidney allograft prolongation after oral exposure to alloantigen. Transpl Int. 2008, 21 (7): 679-87.PubMedCrossRef
57.
go back to reference Chen W: Donor lymphocyte infusion induces long-term donor-specific cardiac xenograft survival through activation of recipient double-negative regulatory T cells. J Immunol. 2005, 175 (5): 3409-16.PubMedCrossRef Chen W: Donor lymphocyte infusion induces long-term donor-specific cardiac xenograft survival through activation of recipient double-negative regulatory T cells. J Immunol. 2005, 175 (5): 3409-16.PubMedCrossRef
58.
go back to reference Deniz G: Regulatory NK cells suppress antigen-specific T cell responses. J Immunol. 2008, 180 (2): 850-7.PubMedCrossRef Deniz G: Regulatory NK cells suppress antigen-specific T cell responses. J Immunol. 2008, 180 (2): 850-7.PubMedCrossRef
59.
go back to reference Fujita H: Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model. J Immunol. 2009, 183 (1): 254-60.PubMedCrossRef Fujita H: Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model. J Immunol. 2009, 183 (1): 254-60.PubMedCrossRef
60.
go back to reference Ishii Y: Alpha-galactosylceramide-driven immunotherapy for allergy. Front Biosci. 2008, 13: 6214-28.PubMedCrossRef Ishii Y: Alpha-galactosylceramide-driven immunotherapy for allergy. Front Biosci. 2008, 13: 6214-28.PubMedCrossRef
62.
go back to reference Denepoux S: Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. FEBS Lett. 2000, 465 (1): 39-46.PubMedCrossRef Denepoux S: Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. FEBS Lett. 2000, 465 (1): 39-46.PubMedCrossRef
63.
64.
go back to reference Wachholz PA, Durham SR: Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol. 2004, 4 (4): 313-8.PubMedCrossRef Wachholz PA, Durham SR: Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol. 2004, 4 (4): 313-8.PubMedCrossRef
65.
go back to reference Gleich GJ: Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol. 1982, 70 (4): 261-71.PubMedCrossRef Gleich GJ: Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol. 1982, 70 (4): 261-71.PubMedCrossRef
67.
go back to reference Fujimoto M: Regulatory B cells in skin and connective tissue diseases. J Dermatol Sci. 2010, 60 (1): 1-7.PubMedCrossRef Fujimoto M: Regulatory B cells in skin and connective tissue diseases. J Dermatol Sci. 2010, 60 (1): 1-7.PubMedCrossRef
68.
go back to reference Bouaziz JD, Yanaba K, Tedder TF: Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev. 2008, 224: 201-14.PubMedCrossRef Bouaziz JD, Yanaba K, Tedder TF: Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev. 2008, 224: 201-14.PubMedCrossRef
69.
go back to reference Fillatreau S, Gray D, Anderton SM: Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol. 2008, 8 (5): 391-7.PubMedCrossRef Fillatreau S, Gray D, Anderton SM: Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol. 2008, 8 (5): 391-7.PubMedCrossRef
70.
go back to reference Mauri C, Ehrenstein MR: The 'short' history of regulatory B cells. Trends Immunol. 2008, 29 (1): 34-40.PubMedCrossRef Mauri C, Ehrenstein MR: The 'short' history of regulatory B cells. Trends Immunol. 2008, 29 (1): 34-40.PubMedCrossRef
71.
go back to reference Yanaba K: The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol. 2009, 182 (12): 7459-72.PubMedCentralPubMedCrossRef Yanaba K: The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol. 2009, 182 (12): 7459-72.PubMedCentralPubMedCrossRef
72.
go back to reference Matsushita T: Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008, 118 (10): 3420-30.PubMedCentralPubMed Matsushita T: Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008, 118 (10): 3420-30.PubMedCentralPubMed
73.
go back to reference Blair PA: Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol. 2009, 182 (6): 3492-502.PubMedCentralPubMedCrossRef Blair PA: Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol. 2009, 182 (6): 3492-502.PubMedCentralPubMedCrossRef
74.
go back to reference Evans JG: Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol. 2007, 178 (12): 7868-78.PubMedCrossRef Evans JG: Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol. 2007, 178 (12): 7868-78.PubMedCrossRef
75.
go back to reference Mizoguchi A: Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002, 16 (2): 219-30.PubMedCrossRef Mizoguchi A: Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002, 16 (2): 219-30.PubMedCrossRef
76.
go back to reference Wei B: Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc Natl Acad Sci USA. 2005, 102 (6): 2010-5.PubMedCentralPubMedCrossRef Wei B: Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc Natl Acad Sci USA. 2005, 102 (6): 2010-5.PubMedCentralPubMedCrossRef
77.
go back to reference Yanaba K: A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008, 28 (5): 639-50.PubMedCrossRef Yanaba K: A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008, 28 (5): 639-50.PubMedCrossRef
78.
79.
go back to reference Devergne O, Birkenbach M, Kieff E: Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA. 1997, 94 (22): 12041-6.PubMedCentralPubMedCrossRef Devergne O, Birkenbach M, Kieff E: Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA. 1997, 94 (22): 12041-6.PubMedCentralPubMedCrossRef
80.
go back to reference Gavin MA: Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007, 445 (7129): 771-5.PubMedCrossRef Gavin MA: Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007, 445 (7129): 771-5.PubMedCrossRef
81.
go back to reference Collison LW: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007, 450 (7169): 566-9.PubMedCrossRef Collison LW: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007, 450 (7169): 566-9.PubMedCrossRef
82.
go back to reference Niedbala W: IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007, 37 (11): 3021-9.PubMedCrossRef Niedbala W: IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007, 37 (11): 3021-9.PubMedCrossRef
84.
go back to reference Amar SM: Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol. 2009, 124 (1): 150-156. e1-5PubMedCrossRef Amar SM: Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol. 2009, 124 (1): 150-156. e1-5PubMedCrossRef
85.
go back to reference Bufe A: Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009, 123 (1): 167-173. e7PubMedCrossRef Bufe A: Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009, 123 (1): 167-173. e7PubMedCrossRef
86.
go back to reference Durham SR: Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010, 125 (1): 131-8. e1-7PubMedCrossRef Durham SR: Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010, 125 (1): 131-8. e1-7PubMedCrossRef
87.
go back to reference Horak F: Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009, 124 (3): 471-7. 477 e1PubMedCrossRef Horak F: Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009, 124 (3): 471-7. 477 e1PubMedCrossRef
88.
go back to reference Skoner D: Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol. 2010, 125 (3): 660-6. 666 e1-666 e4PubMedCrossRef Skoner D: Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol. 2010, 125 (3): 660-6. 666 e1-666 e4PubMedCrossRef
89.
go back to reference Blumchen K: Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010, 126 (1): 83-91 e1.PubMedCrossRef Blumchen K: Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010, 126 (1): 83-91 e1.PubMedCrossRef
90.
go back to reference Crameri R, Kundig TM, Akdis CA: Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol. 2009, 9 (6): 568-73.PubMedCrossRef Crameri R, Kundig TM, Akdis CA: Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol. 2009, 9 (6): 568-73.PubMedCrossRef
91.
92.
go back to reference Senti G: Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009, 124 (5): 997-1002.PubMedCrossRef Senti G: Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009, 124 (5): 997-1002.PubMedCrossRef
93.
go back to reference Thalhamer T: Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening. J Allergy Clin Immunol. 2010, 125 (4): 926-934. e10PubMedCrossRef Thalhamer T: Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening. J Allergy Clin Immunol. 2010, 125 (4): 926-934. e10PubMedCrossRef
94.
go back to reference Marcucci F: Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int J Immunopathol Pharmacol. 2008, 21 (3): 609-13.PubMed Marcucci F: Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int J Immunopathol Pharmacol. 2008, 21 (3): 609-13.PubMed
95.
go back to reference Allam JP: Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol. 2003, 112 (1): 141-8.PubMedCrossRef Allam JP: Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol. 2003, 112 (1): 141-8.PubMedCrossRef
96.
go back to reference Allam JP: Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?. Allergy. 2008, 63 (6): 720-7.PubMedCrossRef Allam JP: Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?. Allergy. 2008, 63 (6): 720-7.PubMedCrossRef
97.
go back to reference Allam JP: Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol. 2008, 121 (2): 368-374. e1PubMedCrossRef Allam JP: Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol. 2008, 121 (2): 368-374. e1PubMedCrossRef
98.
go back to reference Scadding GW: Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 2010, 40 (4): 598-606.PubMed Scadding GW: Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 2010, 40 (4): 598-606.PubMed
99.
go back to reference Cox L: Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010, 125 (3): 569-74. 574 e1-574 e7PubMedCrossRef Cox L: Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010, 125 (3): 569-74. 574 e1-574 e7PubMedCrossRef
100.
go back to reference Jacobsen L: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007, 62 (8): 943-8.PubMedCrossRef Jacobsen L: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007, 62 (8): 943-8.PubMedCrossRef
101.
go back to reference Werfel T: Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006, 61 (2): 202-5.PubMedCrossRef Werfel T: Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006, 61 (2): 202-5.PubMedCrossRef
102.
go back to reference Asturias JA: Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy. 2009, 39 (7): 1088-98.PubMedCrossRef Asturias JA: Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy. 2009, 39 (7): 1088-98.PubMedCrossRef
103.
go back to reference Martinez-Gomez JM: Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy. 2009, 64 (1): 172-8.PubMedCrossRef Martinez-Gomez JM: Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy. 2009, 64 (1): 172-8.PubMedCrossRef
104.
go back to reference Martinez-Gomez JM: Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009, 150 (1): 59-65.PubMedCrossRef Martinez-Gomez JM: Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009, 150 (1): 59-65.PubMedCrossRef
105.
go back to reference Roll A: Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol. 2006, 16 (2): 79-85.PubMed Roll A: Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol. 2006, 16 (2): 79-85.PubMed
106.
go back to reference Mamessier E: Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy. 2006, 36 (6): 704-13.PubMedCrossRef Mamessier E: Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy. 2006, 36 (6): 704-13.PubMedCrossRef
107.
go back to reference Roger A: Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mites. Int Arch Allergy Immunol. 2011, 154 (1): 69-75.PubMedCrossRef Roger A: Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mites. Int Arch Allergy Immunol. 2011, 154 (1): 69-75.PubMedCrossRef
Metadata
Title
Mechanisms of allergen-specific immunotherapy
Authors
Hiroyuki Fujita
Michael B Soyka
Mübeccel Akdis
Cezmi A Akdis
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Clinical and Translational Allergy / Issue 1/2012
Electronic ISSN: 2045-7022
DOI
https://doi.org/10.1186/2045-7022-2-2

Other articles of this Issue 1/2012

Clinical and Translational Allergy 1/2012 Go to the issue